A balancing act: Orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression

Oncogene

Volumn 34, Issue 33, 2015, Pages 4287-4299

  Engelmann, D ^a   Meier, C ^a   Alla, V ^a   Putzer B M ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL SEQUENCE TRUNCATED PROTEIN P73; PROTEIN P73; PROTEIN VARIANT; TAP73 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SWITCHING; HUMAN; METABOLISM; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REDOX STRESS; REGULATORY MECHANISM; REPRESSOR GENE; TUMOR INVASION; ANIMAL; DISEASE COURSE; NEOPLASM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84939568676     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.365     Document Type: Article

References (201)

1. Buhlmann S, Putzer BM. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 2008; 1785: 207-216.
2. Niemantsverdriet M, Nagle P, Chiu RK, Langendijk JA, Kampinga HH, Coppes RP. DeltaNp73 enhances promoter activity of TGF-beta induced genes. PLoS One 2012; 7: e50815.
3. Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014; 157: 382-394.
4. Wetterskog D, Moshiri A, Ozaki T, Uramoto H, Nakagawara A, Funa K. Dysregulation of platelet-derived growth factor beta-receptor expression by DeltaNp73 in neuroblastoma. Mol Cancer Res 2009; 7: 2031-2039.
5. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9: 246-251.
6. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64: 2449-2460.
7. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006; 24: 805-815.
8. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F et al. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations. Cell Cycle 2008; 7: 1587-1596.
9. Lau LM, Wolter JK, Lau JT, Cheng LS, Smith KM, Hansford LM et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009; 28: 2024-2033.
10. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-615.
11. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386.
12. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-1577.
13. Soldevilla B, Diaz R, Silva J, Campos-Martin Y, Munoz C, Garcia V et al. Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res 2011; 17: 6029-6039.
14. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10: 626-633.
15. Tuve S, Wagner SN, Schittek B, Putzer BM. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer 2004; 108: 162-166.
16. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 2004; 10: 6905-6911.
17. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z et al. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol 2007; 114: 641-650.
18. Di C, Yang L, Zhang H, Ma X, Zhang X, Sun C et al. Mechanisms, function and clinical applications of DNp73. Cell Cycle 2013; 12: 1861-1867.
19. Soldevilla B, Millan CS, Bonilla F, Dominguez G. The TP73 complex network: ready for clinical translation in cancer? Genes Chromosomes Cancer 2013; 52: 989-1006.
20. Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Furst K et al. DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell 2013; 24: 512-527.
21. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W et al. Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. Oncogene 2010; 29: 5861-5868.
22. Lee CW, La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene 1999; 18: 4171-4181.
23. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18: 447-459.
24. Beitzinger M, Oswald C, Beinoraviciute-Kellner R, Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene 2006; 25: 813-826.
25. Racek T, Mise N, Li Z, Stoll A, Putzer BM. C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter. J Biol Chem 2005; 280: 40402-40405.
26. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22: 2677-2691.
27. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003; 100: 2420-2425.
28. Zaika E, Wei J, Yin D, Andl C, Moll U, El-Rifai W et al. p73 protein regulates DNA damage repair. FASEB J 2011; 25: 4406-4414.
29. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet 2009; 5: e1000680.
30. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 2009; 106: 797-802.
31. Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, Blandino G et al. A role of p73 in mitotic exit. J Biol Chem 2005; 280: 30354-30360.
32. Toh WH, Nam SY, Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ 2010; 17: 787-800.
33. Talos F, Nemajerova A, Flores ER, Petrenko O, Moll UM. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell 2007; 27: 647-659.
34. Candi E, Agostini M, Melino G, Bernassola F. How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat 2014; 35: 702-714.
35. Logotheti S, Pavlopoulou A, Galtsidis S, Vojtesek B, Zoumpourlis V. Functions, divergence and clinical value of TAp73 isoforms in cancer. Cancer Metastasis Rev 2013; 32: 511-534.
36. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008; 27: 6507-6521.
37. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004; 279: 8076-8083.
38. John K, Alla V, Meier C, Putzer BM. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ 2011; 18: 874-886.
39. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
40. Sayan AE, Sayan BS, Gogvadze V, Dinsdale D, Nyman U, Hansen TM et al. P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 2008; 27: 4363-4372.
41. Liu T, Roh SE, Woo JA, Ryu H, Kang DE. Cooperative role of RanBP9 and P73 in mitochondria-mediated apoptosis. Cell Death Dis 2013; 4: e476.
42. Terrinoni A, Ranalli M, Cadot B, Leta A, Bagetta G, Vousden KH et al. p73-alpha is capable of inducing scotin and ER stress. Oncogene 2004; 23: 3721-3725.
43. Guerrieri F, Piconese S, Lacoste C, Schinzari V, Testoni B, Valogne Y et al. The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell Death Dis 2013; 4: e807.
44. Klanrit P, Taebunpakul P, Flinterman MB, Odell EW, Riaz MA, Melino G et al. PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene 2009; 28: 3499-3512.
45. Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 2014; 14: 329-341.
46. Harms KL, Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 2005; 25: 2014-2030.
47. Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One 2012; 7: e42985.
48. Sasaki Y, Mita H, Toyota M, Ishida S, Morimoto I, Yamashita T et al. Identification of the interleukin 4 receptor alpha gene as a direct target for p73. Cancer Res 2003; 63: 8145-8152.
49. Broadhead ML, Dass CR, Choong PF. Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. Trends Mol Med 2009; 15: 461-467.
50. Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y, Tokino T. Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 2005; 24: 5131-5136.
51. Ho TC, Chen SL, Yang YC, Liao CL, Cheng HC, Tsao YP. PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007; 76: 213-223.
52. Diaz R, Pena C, Silva J, Lorenzo Y, Garcia V, Garcia JM et al. p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 2008; 123: 1060-1067.
53. Rastogi S, Rizwani W, Joshi B, Kunigal S, Chellappan SP. TNF-alpha response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73. Cell Death Differ 2012; 19: 274-283.
54. Yamamura Y, Lee WL, Goh MX, Ito Y. Role of TAp73alpha in induction of apoptosis by transforming growth factor-beta in gastric cancer cells. FEBS Lett 2008; 582: 2663-2667.
55. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820.
56. Crighton D, O'Prey J, Bell HS, Ryan KM. p73 regulates DRAM-independent autophagy that does not contribute to programmed cell death. Cell Death Differ 2007; 14: 1071-1079.
57. Liu K, Shi Y, Guo X, Wang S, Ouyang Y, Hao M et al. CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2. Cell Death Dis 2014; 5: e1323.
58. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008; 28: 5951-5964.
59. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP et al. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ 2013; 20: 1415-1424.
60. Schipper H, Alla V, Meier C, Nettelbeck DM, Herchenroder O, Putzer BM. Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus. Oncotarget 2014; 5: 5893-5907.
61. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 2012; 26: 2009-2014.
62. Dixit D, Ghildiyal R, Anto NP, Sen E. Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism. Cell Death Dis 2014; 5: e1212.
63. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis 2014; 5: e1065.
64. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol 2013; 15: 991-1000.
65. Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P et al. p73 regulates serine biosynthesis in cancer. Oncogene 2014; 33: 5039-5046.
66. Conforti F, Yang AL, Agostini M, Rufini A, Tucci P, Nicklison-Chirou MV et al. Relative expression of TAp73 and DeltaNp73 isoforms. Aging (Albany NY) 2012; 4: 202-205.
67. Petrenko O, Zaika A, Moll UM. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 2003; 23: 5540-5555.
68. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002; 62: 3598-3602.
69. Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H et al. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 2008; 27: 792-803.
70. Tannapfel A, John K, Mise N, Schmidt A, Buhlmann S, Ibrahim SM et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008; 29: 211-218.
71. Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006; 10: 281-293.
72. Huttinger-Kirchhof N, Cam H, Griesmann H, Hofmann L, Beitzinger M, Stiewe T. The p53 family inhibitor DeltaNp73 interferes with multiple developmental programs. Cell Death Differ 2006; 13: 174-177.
73. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62: 636-641.
74. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
75. Stiewe T, Theseling CC, Putzer BM. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem 2002; 277: 14177-14185.
76. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002; 196: 765-780.
77. Bailey SG, Cragg MS, Townsend PA. Family friction as DeltaNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011; 43: 482-486.
78. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Putzer BM. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem 2003; 278: 14230-14236.
79. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 2006; 12: 3922-3927.
80. Liu SS, Leung RC, Chan KY, Chiu PM, Cheung AN, Tam KF et al. p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res 2004; 10: 3309-3316.
81. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11: 8372-8383.
82. Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F et al. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9: 2629-2639.
83. Simoes-Wust AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U. DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J Neurooncol 2005; 72: 29-34.
84. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 2008; 27: 2170-2176.
85. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11: 3067-3078.
86. Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O et al. Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network. Cancer Res 2013; 73: 3511-3524.
87. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R et al. Isoformspecific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010; 24: 549-560.
88. Lee AF, Ho DK, Zanassi P, Walsh GS, Kaplan DR, Miller FD. Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. J Neurosci 2004; 24: 9174-9184.
89. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P et al. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer 2009; 124: 2539-2548.
90. Nahor I, Abramovitch S, Engeland K, Werner H. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res 2005; 15: 388-396.
91. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-695.
92. Zhang Y, Yan W, Jung YS, Chen X. Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition. J Biol Chem 2012; 287: 17746-17753.
93. Zhang Y, Yan W, Jung YS, Chen X. PUMA cooperates with p21 to regulate mammary epithelial morphogenesis and epithelial-to-mesenchymal transition. PLoS One 2013; 8: e66464.
94. Puppin C, Passon N, Frasca F, Vigneri R, Tomay F, Tomaciello S et al. In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. Cell Oncol (Dordr) 2011; 34: 131-140.
95. Hackzell A, Uramoto H, Izumi H, Kohno K, Funa K. p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J Biol Chem 2002; 277: 39769-39776.
96. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
97. Lin Y, Cheng Z, Yang Z, Zheng J, Lin T. DNp73 improves generation efficiency of human induced pluripotent stem cells. BMC Cell Biol 2012; 13: 9.
98. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014; 5: 3472.
99. Luh LM, Kehrloesser S, Deutsch GB, Gebel J, Coutandin D, Schafer B et al. Analysis of the oligomeric state and transactivation potential of TAp73alpha. Cell Death Differ 2013; 20: 1008-1016.
100. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005; 24: 836-848.
101. Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci USA 2007; 104: 11280-11285.
102. Hosoda M, Ozaki T, Miyazaki K, Hayashi S, Furuya K, Watanabe K et al. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 2005; 24: 7156-7169.
103. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005; 19: 316-321.
104. Zhang J, Xu E, Chen X. TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function. J Biol Chem 2013; 288: 7727-7737.
105. Yan W, Zhang J, Zhang Y, Jung YS, Chen X. p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol 2012; 32: 2336-2348.
106. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP et al. Cyclindependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 2003; 278: 27421-27431.
107. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14: 743-751.
108. Kim EJ, Park JS, Um SJ. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem 2002; 277: 32020-32028.
109. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008; 32: 803-814.
110. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005; 7: 278-285.
111. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519.
112. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523.
113. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 1999; 399: 809-813.
114. Levy D, Adamovich Y, Reuven N, Shaul Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol Cell 2008; 29: 350-361.
115. Levy D, Reuven N, Shaul Y. A regulatory circuit controlling Itch-mediated p73 degradation by Runx. J Biol Chem 2008; 283: 27462-27468.
116. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 2004; 14: 625-636.
117. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell 2002; 9: 175-186.
118. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 2002; 21: 974-979.
119. Yuan ZM, Utsugisawa T, Ishiko T, Nakada S, Huang Y, Kharbanda S et al. Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene 1998; 16: 1643-1648.
120. Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V et al. p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem 2002; 277: 33758-33765.
121. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
122. Jones EV, Dickman MJ, Whitmarsh AJ. Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J 2007; 405: 617-623.
123. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004; 279: 44713-44722.
124. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004; 24: 1341-1350.
125. Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 2008; 36: 5139-5151.
126. Sang M, Li Y, Ozaki T, Ono S, Ando K, Yamamoto H et al. p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers. Biochem Biophys Res Commun 2006; 347: 327-333.
127. Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. J Biol Chem 2011; 286: 36631-36640.
128. Watanabe K, Ozaki T, Nakagawa T, Miyazaki K, Takahashi M, Hosoda M et al. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J Biol Chem 2002; 277: 15113-15123.
129. Leung TH, Ngan HY. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiationinduced apoptosis. Cancer Res 2010; 70: 6486-6496.
130. Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G et al. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res 2009; 69: 5978-5986.
131. Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM et al. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci USA 2013; 110: 17969-17974.
132. Wei WL, Hu HY, Zhang LJ, Chen Y, Ye E, Wang XF. [Promoter methylation of ASPP1 and ASPP2 genes in non-small cell lung cancers]. Zhonghua Bing Li Xue Za Zhi 2011; 40: 532-536.
133. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ et al. Differential control of TAp73 and DNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 2010; 107: 12877-12882.
134. Bunjobpol W, Dulloo I, Igarashi K, Concin N, Matsuo K, Sabapathy K. Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death Differ 2014; 21: 1240-1249.
135. Dulloo I, Gopalan G, Melino G, Sabapathy K. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA 2010; 107: 4902-4907.
136. Chaudhary N, Maddika S. WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and DeltaNp73 levels. Mol Cell Biol 2014.
137. Pan C, Liu HD, Gong Z, Yu X, Hou XB, Xie DD et al. Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site. Sci Rep 2013; 3: 2333.
138. Qian Y, Zhang J, Yan B, Chen X. DEC1, a basic helix-loop-helix transcription factor and a novel target gene of the p53 family, mediates p53-dependent premature senescence. J Biol Chem 2008; 283: 2896-2905.
139. Qian Y, Zhang J, Jung YS, Chen X. DEC1 coordinates with HDAC8 to differentially regulate TAp73 and DeltaNp73 expression. PLoS One 2014; 9: e84015.
140. Kunimoto Y, Nakano S, Kataoka H, Shimada Y, Oshimura M, Kitano H. Deleted in Esophageal Cancer 1(DEC1) is down-regulated and contributes to migration in head and neck squamous cell carcinoma cell lines. ORL J Otorhinolaryngol Relat Spec 2011; 73: 17-23.
141. Liu Y, Wang L, Lin XY, Wang J, Yu JH, Miao Y et al. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in nonsmall-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells. Tumour Biol 2013; 34: 1641-1650.
142. Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 2011; 16: 35-44.
143. Kubo N, Okoshi R, Nakashima K, Shimozato O, Nakagawara A, Ozaki T. MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells. Biochem Biophys Res Commun 2010; 403: 405-411.
144. Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 2009; 28: 3157-3166.
145. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275: 36316-36323.
146. Munarriz E, Barcaroli D, Stephanou A, Townsend PA, Maisse C, Terrinoni A et al. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol 2004; 24: 10593-10610.
147. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
148. Sang M, Ando K, Okoshi R, Koida N, Li Y, Zhu Y et al. Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation. Genes Cells 2009; 14: 775-788.
149. Koida N, Ozaki T, Yamamoto H, Ono S, Koda T, Ando K et al. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 2008; 283: 8555-8563.
150. Tyagi S, Bhui K, Singh R, Singh M, Raisuddin S, Shukla Y. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73alpha in p53 mutant human epidermoid squamous carcinoma cells. Biochem Pharmacol 2010; 80: 1326-1334.
151. Li L, Wang M, Yu G, Chen P, Li H, Wei D et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. J Natl Cancer Inst 2014; 106: dju083.
152. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 2006; 281: 34096-34103.
153. Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 2012; 21: 196-211.
154. Di Vinci A, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C et al. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol 2009; 34: 449-456.
155. Paliwal P, Radha V, Swarup G. Regulation of p73 by Hck through kinasedependent and independent mechanisms. BMC Mol Biol 2007; 8: 45.
156. Blanch A, Robinson F, Watson IR, Cheng LS, Irwin MS. Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity. PLoS One 2013; 8: e66436.
157. Potu H, Peterson LF, Pal A, Verhaegen M, Cao J, Talpaz M et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget 2014; 5: 5559-5569.
158. Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN et al. Global DNA hypomethylation-induced DeltaNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett 2011; 300: 79-86.
159. Casciano I, Banelli B, Croce M, Allemanni G, Ferrini S, Tonini GP et al. Role of methylation in the control of DeltaNp73 expression in neuroblastoma. Cell Death Differ 2002; 9: 343-345.
160. Lai J, Nie W, Zhang W, Wang Y, Xie R, Wang Y et al. Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer. Oncotarget 2014; 5: 6909-6922.
161. Castillo J, Goni S, Latasa MU, Perugorria MJ, Calvo A, Muntane J et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors. Gastroenterology 2009; 137: 1805-1815 e1801-e1804.
162. Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY. The interaction between C35 and DeltaNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer 2013; 109: 965-975.
163. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011; 128: 301-313.
164. Adamovich Y, Adler J, Meltser V, Reuven N, Shaul Y. AMPK couples p73 with p53 in cell fate decision. Cell Death Differ 2014; 21: 1451-1459.
165. Hamilton G, Abraham AG, Morton J, Sampson O, Pefani DE, Khoronenkova S et al. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget 2014; 5: 6142-6167.
166. Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L et al. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res 2014; 74: 1153-1165.
167. Uppada SB, Erickson T, Wojdyla L, Moravec DN, Song Z, Cheng J et al. Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. Int J Nanomedicine 2014; 9: 43-53.
168. Emmrich S, Wang W, John K, Li W, Putzer BM. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer 2009; 8: 61.
169. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-6307.
170. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/ APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010; 29: 6442-6451.
171. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013; 12: 2331-2341.
172. Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H et al. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 2010; 136: 1597-1604.
173. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009; 113: 3744-3753.
174. Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther 2011; 336: 596-604.
175. Christopherson RI, Mactier S, Almazi JG, Kohnke PL, Best OG, Mulligan SP. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells. Nucleosides Nucleotides Nucleic Acids 2014; 33: 375-383.
176. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008; 68: 8998-9004.
177. Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci USA 2011; 108: 2076-2081.
178. Tiwary R, Yu W, Sanders BG, Kline K. alpha-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res 2011; 13: R1.
179. Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S et al. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res 2011; 3: 374-382.
180. Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013; 19: 3808-3819.
181. Das R, Bhattacharya K, Sarkar S, Samanta SK, Pal BC, Mandal C. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma. Apoptosis 2014; 19: 149-164.
182. Alonso R, Lopez-Guerra M, Upshaw R, Bantia S, Smal C, Bontemps F et al. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 2009; 114: 1563-1575.
183. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010; 115: 2619-2629.
184. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009; 113: 1513-1521.
185. Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J et al. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 2010; 79: 1251-1260.
186. Alhosin M, Ibrahim A, Boukhari A, Sharif T, Gies JP, Auger C et al. Anti-neoplastic agent thymoquinone induces degradation of alpha and beta tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs 2012; 30: 1813-1819.
187. Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D et al. ( ? )-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int J Oncol 2011; 38: 1403-1408.
188. Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD et al. Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. Biochem Biophys Res Commun 2013; 430: 208-212.
189. Stearns ME, Wang M. Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl Oncol 2011; 4: 147-156.
190. Sharif T, Auger C, Alhosin M, Ebel C, Achour M, Etienne-Selloum N et al. Red wine polyphenols cause growth inhibition and apoptosis in acute lymphoblastic leukaemia cells by inducing a redox-sensitive up-regulation of p73 and downregulation of UHRF1. Eur J Cancer 2010; 46: 983-994.
191. Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y et al. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaBmediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol 2010; 27: 833-842.
192. Zheng T, Yin D, Lu Z, Wang J, Li Y, Chen X et al. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma. Mol Cancer 2014; 13: 133.
193. Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C et al. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett 2014; 343: 14-23.
194. Wojdyla L, Stone AL, Sethakorn N, Uppada SB, Devito JT, Bissonnette M et al. T-oligo as an anticancer agent in colorectal cancer. Biochem Biophys Res Commun 2014; 446: 596-601.
195. Wolter JK, Wolter NE, Blanch A, Partridge T, Cheng L, Morgenstern DA et al. Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. Oncotarget 2014; 5: 161-172.
196. Park GB, Kim YS, Kim D, Kim S, Lee HK, Cho DH et al. Melphalan-induced apoptosis of EBV-transformed B cells through upregulation of TAp73 and XAF1 and nuclear import of XPA. J Immunol 2013; 191: 6281-6291.
197. Decrion-Barthod AZ, Bosset M, Plissonnier ML, Marchini A, Nicolier M, Launay S et al. Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells. Anticancer Res 2010; 30: 4049-4061.
198. Tebbi A, Guittet O, Cottet MH, Vesin MF, Lepoivre M. TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis. J Biol Chem 2011; 286: 7873-7884.
199. Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW et al. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics 2009; 6: 93-99.
200. Papoutsaki M, Lanza M, Marinari B, Nistico S, Moretti F, Levrero M et al. The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermatol 2004; 123: 1162-1168.
201. Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 2011; 30: 2670-2678.